<DOC>
	<DOCNO>NCT02362490</DOCNO>
	<brief_summary>Antiviral therapy important method slow stop progress disease patient chronic hepatitis B ( CHB ) . Nucleoside ( acid ) analogue ( NA ) Effectively suppress HBV replication , continue use relapse would happen patient withdrawal therapy . However , long-term use NA could induce viral resistance mutation lead loss efficacy . Interferon treatment enhance specific non-specific immune function chronic hepatitis B patient , make patient get immune control HBV infection obtain sustained response treatment . Thus CHB patient treatment NA stop NA treatment interferon treatment . In study , effect interferon treatment CHB patient NA treatment obtain HBsAg level≤250 IU/ml .</brief_summary>
	<brief_title>Efficacy Peginterferon Alpha 2a Therapy Chronic Hepatitis B Patients Being Treated With Nucleoside ( Acid ) Analogues</brief_title>
	<detailed_description>In trial , patient CHB treat NA 6 month , still treatment achieve HBsAg level ≤250 IU/ml HBV DNA undetectable randomize enrol group A ( Intervention group ) , patient switch interferon therapy 72 week , group B ( control group ) , patient continue treat NA 72 week . Serum HBV DNA load , HBsAg/anti-HBs level , HBeAg/anti-HBe test enrollment every 3 month treatment course . Parameters Liver kidney function , liver ultrasound examination test interval 1-3 month . The efficacy interferon treatment devalue rate HBsAg clearance decline HBsAg level 72 week interferon treatment compare control group .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>patient chronic hepatitis B achieve HBsAg level ≤250 IU/ml treatment Nucleoside ( acid ) Analogues Active consumption alcohol and/or drug Coinfection human immunodeficiency virus , hepatitis C virus , hepatitis D virus History autoimmune hepatitis Psychiatric disease Evidence neoplastic disease liver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>chronic hepatitis B</keyword>
	<keyword>interferon</keyword>
	<keyword>Nucleotide analogue</keyword>
	<keyword>HBsAg</keyword>
</DOC>